Table 2.
Karyotypes | Single ACA | In combination with other ACA | Total |
---|---|---|---|
High-risk ACA (n = 91)a | |||
+8 | 19 | 19 | 38 |
At diagnosis | 6 | 10 | 16 |
In the course of disease | 13 | 9 | 22 |
+Ph | 18 | 17 | 35 |
At diagnosis | 7 | 6 | 13 |
In the course of disease | 11 | 11 | 22 |
+19 | 0 | 11 | 11 |
At diagnosis | 0 | 4 | 4 |
In the course of disease | 0 | 7 | 7 |
+17/i(17q) | 3 | 5 | 8 |
At diagnosis | 1 | 3 | 4 |
In the course of disease | 2 | 2 | 4 |
3q26.2 | 10 | 2 | 12 |
At diagnosis | 1 | 0 | 1 |
In the course of disease | 9 | 2 | 9 |
−7/7q abnormalities | 5 | 4 | 9 |
At diagnosis | 1 | 0 | 1 |
In the course of disease | 4 | 4 | 8 |
+21 | 2 | 3 | 5 |
At diagnosis | 1 | 1 | 2 |
In the course of disease | 1 | 2 | 3 |
11q23 | 1 | 0 | 1 |
At diagnosis | 0 | 0 | 0 |
In the course of disease | 1 | 0 | 1 |
Complex karyotypes | 25 | 25 | |
At diagnosis | 11 | 11 | |
In the course of disease | 14 | 14 | |
Low-risk ACA | 32 | 32 | |
At diagnosis | 19 | 19 | |
In the course of disease | 13 | 13 |
aMultiple listings possible.